Eslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures
about
Pharmacokinetics and drug interactions of eslicarbazepine acetate.Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.Practice Update: Review of Anticonvulsant Therapy.Emerging drugs for epilepsy.Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampusPerspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Evaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis.Epilepsy in the elderly: facts and challenges.Pharmacotherapy of epilepsy: newly approved and developmental agents.Novel medications for epilepsy.Eslicarbazepine acetate for partial-onset seizures.Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective.Pharmacotherapy for tonic-clonic seizures.Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.Drug-induced cerebellar ataxia: a systematic review.Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures.Eslicarbazepine acetate for the treatment of partial epilepsy.Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy.Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy.Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures.Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.Anticonvulsant Activity of Enantiomeric N-trans-Cinnamoyl Derivatives of 2-Aminopropan-1-ols and 2-Aminobutan-1-ols.Eslicarbazepine acetate: a new option for the treatment of focal epilepsyEvaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study
P2860
Q34276263-E51EC84C-AB6A-453A-93D7-7A85CD97BCDEQ34375311-4E1171BD-5009-41E5-B20E-BEC7680BD4E2Q34518509-9886EDE6-6F04-4B95-9D51-CDBC7643DBBBQ34688725-E0B43DE6-F849-4999-B1B1-C9A67A2AEFB5Q35531026-FD6A1C16-EF4F-40DF-9244-DF3C5FEC3F59Q35761335-8355AC80-2A00-4E36-9998-7B38B43C5DDDQ36284727-9DC30F89-C09C-4073-A30C-42CD974E47BBQ37818528-01B2DBC3-B59F-404C-8D05-AC4D7096F030Q37831297-09FFAC1A-2E6F-4616-BDE2-EA5A743E10BFQ37950518-5135FCF9-98AB-495B-A5B3-36BE45A17ABDQ37957121-113F867A-0F16-4DE3-B9D5-74D6D6C67E74Q37968623-7DF4E6A1-667D-4930-8315-C1B8FEF3D5B7Q38199973-21D82496-6C55-446B-8C2A-DA98BF18FF9DQ38209529-259C7730-1308-4CFC-B164-371C15A3AC57Q38223958-CE7BCEBC-406D-4B95-802B-D7921FD4B5B6Q38267726-88DAE8EF-9C3A-4273-8E46-24155D2AE247Q38367761-B72C2EFD-2A09-4B41-87E1-F47858FDE6C0Q38542064-78FD06A4-83D5-4AA5-AF79-D607526D79A8Q38826584-6EFEF77E-8891-4F50-A28C-C80D9EC39E51Q39456360-16E5CA4C-F29D-47BE-B577-590D2DAD5516Q42956261-6CF2BD80-70D4-4225-AFB2-81C7583A2DB6Q44062629-28F78362-3151-4377-8ED0-B49175EFFA7DQ46265751-A10AD000-3E40-4851-8E6F-AB6CCFB2B0DEQ46570612-849B01E8-606F-4892-ABCB-084362C93179Q47326787-CA7E5A9E-D21A-4005-990C-695AD4A2C67DQ47724046-EFFC265A-A938-48C1-A291-DE085F77D2C1Q48424510-4579EB7E-22C0-4AB2-9C20-80DF7AAC96E0Q53112986-D173C8BF-554E-48F6-A3A8-0398D7C9965BQ58870328-A6F71DC3-14C4-4603-9848-F10F9678E4A6Q59284818-F59C8365-BCD2-4525-AE1B-E54C945B92D3
P2860
Eslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures
description
im Februar 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 21 February 2007
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2007
@uk
name
Eslicarbazepine Acetate: A Dou ...... ts with Partial-onset Seizures
@en
Eslicarbazepine Acetate: A Dou ...... ts with Partial-onset Seizures
@nl
type
label
Eslicarbazepine Acetate: A Dou ...... ts with Partial-onset Seizures
@en
Eslicarbazepine Acetate: A Dou ...... ts with Partial-onset Seizures
@nl
prefLabel
Eslicarbazepine Acetate: A Dou ...... ts with Partial-onset Seizures
@en
Eslicarbazepine Acetate: A Dou ...... ts with Partial-onset Seizures
@nl
P2093
P2860
P1433
P1476
Eslicarbazepine acetate: a dou ...... ts with partial-onset seizures
@en
P2093
Christian Elger
Joana Maia
Joyce A Cramer
Meir Bialer
P2860
P304
P356
10.1111/J.1528-1167.2007.00984.X
P577
2007-02-21T00:00:00Z